Jacobson Pharma (HKG:2633) recorded a profit attributable to shareholders of HK$140.3 million for the six months ended Sept. 30, 8.9% lower than HK$154.0 million a year ago.
Earnings per share fell to HK$0.0707 from HK$0.0806 in the year-ago period.
The profit decline resulted from no longer consolidating the results of JBM Healthcare, a Thursday filing with the Hong Kong Exchange said.
The drugmaker's revenue was HK$810 million, up 13.3% from HK$714.9 million a year earlier.
The company attributed the higher revenue to the robust performance of its generic drug business and additional income from newly launched and newly in-licensed products.
The board recommended an interim dividend of HK$0.035 per share, compared to HK$0.025 per share last year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。